Massive Bio, a provider of AI-driven oncology solutions, announced the launch of its latest product, the "Drug Utilization Optimizer (DUO)," at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. The DUO platform is developed to restructure how pharmaceutical commercial teams communicate with physicians and collect data.
DUO provides real-time insights, identifies key physicians conducting certain diagnostic testing at the local, regional, and country levels, and enhances brand revenues while minimizing sales costs. It also enables access to clinical and genomic data for precision targeting that goes beyond traditional data sources. Additionally, DUO helps promote testing for patients who need it and provides an industry-wide network of oncology experts.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.